stockrow
Saturday 7 November 2026
Export SLS’s income statement to Excel — free account
SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $1.0 million.
- EPS
- +28.6%
- Free cash flow
- −3.52%
Quarter to June 2026, against a year earlier
8.42
0.54
+6.85%
Follow SLS
Alert me
SELLAS Life Sciences Group, Inc. (SLS) P/E ratio
SELLAS Life Sciences Group, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 2.7× (December 2020) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2022 | 0.0× | — |
| Jun 2021 | 0.0× | — |
| Mar 2021 | 0.0× | — |
| Dec 2020 | 0.0× | — |
Against its own ten years
Low 0.0×
High 2.7×
Ten-year median
0.0×
Current reading's percentile
96
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ABSI Absci Corporation compare | n/m |
| SLS SELLAS Life Sciences Group, Inc. | n/m |
| GENB Generate Biomedicines, Inc. compare | n/m |
| RARE Ultragenyx Pharmaceutical Inc. compare | n/m |
| KLRA Kailera Therapeutics, Inc. compare | n/m |
| NTLA Intellia Therapeutics, Inc. compare | n/m |
| NVAX Novavax, Inc. compare | n/m |
| NRIX Nurix Therapeutics, Inc. compare | 6.1× |
| BRVE Braveheart Bio, Inc. compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)